Loading data for KLRS — first visit, this takes a few seconds.
Kalaris Therapeutics, Inc. (KLRS)
NasdaqGM: KLRS
· Real-Time Price · USD
3.38
+0.08 (2.42%)
At close: Sep 11, 2026, 3:59 PM
3.48
+2.96%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Kalaris Therapeutics, Inc. (KLRS) Stock Price, Analysis & Data
2.42% (1D)
| Bid | 3.12 |
| Market Cap | 80.5M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -44.3M |
| 0.00 | |
| -1.9 | |
| n/a | |
| -2.04 | |
| P/B (ttm) | 1.39 |
| P/S (ttm) | 0.00 |
| Earnings Date | Aug 7, 2025 |
| Ask | 5.6 |
| Volume | 87,093 |
| Avg. Volume (20D) | 255,317 |
| Open | 3.34 |
| Previous Close | 3.30 |
| Day's Range | 3.29 - 3.44 |
| 52-Week Range | 3.03 - 11.88 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About KLRS
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therape...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2020
Employees 20
Stock Exchange NasdaqGM
Ticker Symbol KLRS
Website https://kalaristx.com
Financial Performance
In 2025, Kalaris Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -43.44M, a decrease of -37.2%.
Financial StatementsEarnings Surprise
Kalaris Therapeutics has released their quarterly earnings on Aug 11, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.48 exceeds estimates by 0.01, with 21.31% YoY growth.
Kalaris Therapeutics, Inc. is scheduled to release its earnings on Aug 7, 2025, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
